A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This is a phase 3, multi-center, randomized, placebo-controlled, double-blind, parallel-group
study with an equal randomization among the Hemay005 high dose, lower dose and placebo
treatment groups. After subject randomization, each subject will enter an core-treatment
Phase for 12 weeks following an extended-treatment phase for another 40 weeks and a follow up
phase for 4weeks.